Etrasimod for elderly patients with ulcerative colitis
Part of Digestive system clinical trials.
This trial tests an oral medication called etrasimod for elderly patients with active ulcerative colitis. It aims to see if the drug is safe and effective in reducing inflammation and symptoms.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have active ulcerative colitis (UC) right now.
- You cannot have kidney failure (acute or chronic).
- You cannot have chronic heart disease or a lung infection.
- You cannot have liver cirrhosis, colorectal cancer, or an autoimmune disease.
- You cannot have an infectious disease.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether etrasimod can improve ulcerative colitis (UC) symptoms in adolescents with moderate to severe, active disease. It may help reduce inflammation and disease activity, especially if current treatments aren’t working well enough.
This trial tests if the medicine etrasimod can help children with moderate to severe ulcerative colitis. You may still be able to join even if you are already taking other treatments for your condition.
This study watches how well etrasimod works for adults with moderate to severe ulcerative colitis (UC). You must already be prescribed etrasimod by your doctor, and the study collects information through a web-based tool.
This study is looking at how well etrasimod works for people with active ulcerative colitis. If you are already taking etrasimod and started it within the last 6 months, you may be able to join and help researchers learn more about its benefits.
This trial tests if etrasimod can prevent pouchitis, which is inflammation of the surgically created internal pouch, in people who have had their colon removed due to ulcerative colitis. If you are at high risk for pouchitis or have had only one episode, this study may help keep your pouch healthy.
This trial compares two medicines — etrasimod (a new pill) and mesalazine (a standard anti-inflammatory) — to see which works better and is safer for Chinese adults with active ulcerative colitis. Participants will receive one of the two treatments, and the study aims to find if the newer drug offers more benefit.
Hear when a new Ulcerative Colitis (Disorder) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.